NCT05609162 (TBMPPF) is a clinical trial of neurosurgical resection in Brain Metastases, sponsored by Sun Yat-sen University.

Who is sponsoring NCT05609162?

NCT05609162 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT05609162?

Interventions in NCT05609162: neurosurgical resection.

What condition does NCT05609162 study?

NCT05609162 studies Brain Metastases.

Is NCT05609162 still recruiting?

NCT05609162 is currently status unknown. Last updated 15 December 2022.

Last reviewed 2022-12-15 · How we verify

NCT05609162: TBMPPF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatments for Brain Metastases With Poor Prognostic Factors

Status unknown Last updated 15 December 2022

What this trial tests

trial testing neurosurgical resection in Brain Metastases in 2,000 participants. Status unknown.

Timeline

15 December 2022

Primary endpoint
20 November 2023

20 November 2024

Quick facts

Lead sponsor	Sun Yat-sen University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	2,000
Start date	15 December 2022
Primary completion	20 November 2023
Estimated completion	20 November 2024
Sites	1 location across China

Drugs / interventions tested

neurosurgical resection

Conditions studied

Brain Metastases — all drugs for Brain Metastases →

Sponsor

Sun Yat-sen University

Who can join

Eligibility, any sex, with Brain Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to learn about treatments in brain metastases with poor prognostic factors. The main questions it aims to answer are: * What kind of local treatment provides a survival benefit for patients with poor prognostic factors? * What kind of systemic treatment provides a survival benefit for patients with poor prognostic factors? * Will the combination of local treatment and systemic treatment provide a survival benefit for patients with poor prognostic factors? Participants will be asked to provide personal information about their living status, symptoms, and disease control during the follow-up.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Survival Benefits of Radiotherapy and Surgery in Lung Cancer Brain Metastases with Poor Prognosis Factors.
Liang L, Wang Z, Duan H, He Z, et al · · 2023 · cited 5× · PMID 36826133 · DOI 10.3390/curroncol30020172
Poor Karnofsky performance status is not a contraindication for neurosurgical resection in patients with lung cancer brain metastases: a multicenter, retrospective PSM-IPTW cohort study.
Liang L, Wen L, Qin S, He Z, et al · · 2023 · cited 3× · PMID 36940052 · DOI 10.1007/s11060-023-04293-8
Prognostic Analysis of Lung Cancer With Brain Metastases in Elderly Patients: A Multicenter Retrospective Study.
Li A, Feng D, Liu C, Huang C, et al · · 2025 · PMID 41531790 · DOI 10.1002/agm2.70060

Verify or expand the search:

Other recruiting trials for Brain Metastases

Currently open trials in the same condition.

NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07481786 — Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases · Phase 3 · recruiting
NCT07227610 — Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT) · Phase 2 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
NCT07053033 — Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR Be · Phase 2 · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05609162 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 15 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05609162.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing